title: [The clinical characteristics and outcomes of 16 Burkitt' s lymphoma with testicular involvement].
abstract: Objective:To analyze the clinical features and outcomes of Burkitt lymphoma with testicular involvement and study the efficiency of high dose methotrexate (HD-MTX: 5-8g/m2) in those patients without radiation therapy.Method:Retrospective analysis was conducted in 16 Burkitt's lymphoma cases with testicular lymphoma involvement between Jan 2009 and Dec 2014. We followed the BCH-NHL-2009 protocol, modified from FAB LMB 89 combined with rituximab. All patients were enrolled in high-risk group (treated by Group C protocol).Results:Of 137 Burkitt lymphoma, 16 (11.67% ) had testicular involvement. All the patients were in stage Ⅳ, the median age was 6.65 years (ranges: 2.25 to 13.5 years). 8 cases had bone marrow involvement, 9 with central nervous system involvement, 5 with bi-testicular involvement, 1 with EB virus infection (EBV-IgM+). The median follow-up was 31.8 months (ranges: 0.5 to 79 months). During the study period, 2 cases died, 1 due to the disease relapse, the other one due to chemo-related dead. 1 had disease relapse 32 months after off treatment; the other 13 cases were all event free survival. 3-year OS was 87.5%, 3-year EFS was 72.9%. We also found the level of testosterone in ten adolescent were normal before and after chemotherapy.Conclusion:For the Burkitt lymphoma with testicular involvement, we abandon radiotherapy, and administer HD-MTX to lower the toxicity. The short-term survival is better, long-term survival still needs to be clarified.
authors.affiliation: Center of Hematology , Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: S
authors.initials: S
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Jin
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: Y L
authors.initials: YL
authors.lastname: Duan
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: C J
authors.initials: CJ
authors.lastname: Zhou
authors.forename: Y H
authors.initials: YH
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D012189:Retrospective Studies; D000069283:Rituximab; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D003561:Cytarabine; D000069283:Rituximab; D003520:Cyclophosphamide; D008727:Methotrexate